Dr. Kam Shojania
Because no two people with an inflammatory (autoimmune) form of arthritis respond to the same medication in the same way—and many do not respond nearly well enough or at all—there is a need for more medications to treat this serious group of diseases.
The good news is that research into new treatment options is ongoing. Here we discuss two not yet available “small molecule” medications that work in a whole new way, plus a biologic that has been newly approved by Health Canada. To help us gain a better understanding of these new and upcoming medications, we spoke with Dr. Kam Shojania, a research scientist at the Arthritis Research Centre of Canada (ARC) and chair of Arthritis Consumer Experts’ advisory board. Continue reading
Fran catching up on her online newspaper reading
A small pleasure—when time permits—is reading a daily newspaper back to front, rather than my usual online skim and swipe. I had time during my winter retreat in Southwest Florida to enjoy the local newspaper although that was a quick read because the news coverage is far below “acceptable”. So I treat the newspaper as what it truly is: a great source for local events and activities, and I read it for its entertainment value.
Help researchers advance the understanding and treatment of gout.
The Gout & Uric Acid Education Society is conducting a brief anonymous survey. They are seeking participation from people living with gout. The survey is for research purposes only. It will only take 2-3 minutes to complete. Please be assured that any information you provide will be strictly confidential and anonymous.
Participation in this survey is voluntary. You are free to stop taking the survey at any time. The information gained from this survey will help researchers advance the understanding and treatment of gout.
If you live with gout, or know someone who does, please share this survey with them. Click here to take the survey.
The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Spondylitis Association (CSA) are pleased to announce an upcoming patient forum on ankylosing spondylitis (AS).
Patients with AS and a family member are invited to attend this free informational event. Lectures and activities include:
- Current concepts on the cause of AS.
- Update on the medical treatment of AS.
- Information non-pharmacologic treatment of AS.
- Ask the experts.
Contact Maria Morales at firstname.lastname@example.org or call 416-603-5800, or complete the registration form, which can be found below. The registration form is also available at www.sparccc.ca and www.spondylitis.ca.
2014 Ankylosing Spondylitis Patient Forum
With two new medications approved by Health Canada this month, the New Year is looking promising for people who live with certain forms of inflammatory arthritis.
So far in 2014, Health Canada has issued Notices of Compliance (NOCs) for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (January 2) and for the treatment of ankylosing spondylitis (January 15), and ustekinumab (Stelara®) for the treatment of psoriatic arthritis (January 21). Continue reading
Criteria for denosumab (Prolia®) for osteoporosis and tocilizumab (Actemra®) for rheumatoid arthritis updated.
The Yukon recently added two medications to its Drug Formulary: denosumab (Prolia®) for osteoporosis and tocilizumab (Actemra®) for rheumatoid arthritis. Both medications are considered an Exception drug under the Pharmacare (seniors plan) and the Chronic Disease Program, which requires an application for the Formulary Working Group to assess. Continue reading